AMLX - Amylyx Pharmaceuticals, Inc.

14.1
-0.950   -6.738%

Share volume: 1,295,910
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$15.05
-0.95
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
47%
Profitability 53%
Dept financing 21%
Liquidity 75%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.84%
1 Month
0.86%
3 Months
3.15%
6 Months
35.06%
1 Year
290.58%
2 Year
-25.98%
Key data
Stock price
$14.10
P/E Ratio 
0.00
DAY RANGE
$13.80 - $14.88
EPS 
-$2.40
52 WEEK RANGE
$3.11 - $17.49
52 WEEK CHANGE
$264.34
MARKET CAP 
1.212 B
YIELD 
N/A
SHARES OUTSTANDING 
109.820 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
2.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,264,184
AVERAGE 30 VOLUME 
$911,333
Company detail
CEO: Joshua B. Cohen
Region: US
Website: amylyx.com
Employees: 200
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Amylyx Pharmaceuticals, Inc. develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid.

Recent news